Eidd 1931, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
1) Product Images from "Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model"
Article Title: Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Journal: Research Square
Figure Legend Snippet: EIDD-1931 inhibits SARS-CoV-2 replication in human lung epithelial Calu-3 cells. Cells were pretreated for 1 hour with differing EIDD-1931 concentrations, followed by infection with SARS-CoV-2 at a MOI of 0.01 for 1 hour. After 1 hour, media was replaced, and cells were cultured in the presence of drug for 24 hours at 37°C in a 5% CO2 incubator. ( A ) Virus yield in the cell supernatant was measured by quantitative RT-PCR of clarified culture supernatant by using primer and probe sets to quantify total viral RNA (N gene; genomic and subgenomic RNA). ( B ) IC 50 values were determined using results from the RT-PCR following log-based transformation of drug concentrations and normalization to percentage inhibition based on diluent alone controls by fitting to drug-dose response curves using Prism software. ( C ) Absence of toxicity ( > 90% viability; shown by dotted line) at highest EIDD-1931 concentration used for analysis of SARS-CoV-2 replication (40μM) was confirmed using CellTiter-Glo® 2.0 Assay (Promega, Corp., Madison, WI, USA) as per manufacturer’s protocol. For A to C, means are shown ± standard deviation.
Techniques Used: Infection, Cell Culture, Quantitative RT-PCR, Reverse Transcription Polymerase Chain Reaction, Transformation Assay, Inhibition, Software, Concentration Assay, Standard Deviation
Figure Legend Snippet: Morphometric analysis of viral antigen and drug concentration in the lungs. ( A ) A longitudinal cross section of the right lung was stained for viral antigen and scanned to measure the total amount of viral antigen present in the lung section. ( B ) EIDD-1931 concentrations in the lungs. ( A and B ) Blue circle, vehicle control; red square, pre-infection treatment; green triangle, post-infection treatment. Summary of results: ( A ) The area of lung staining positive for viral antigen showed a statistically significant difference between both of the MK-4482 treatment groups, compared to vehicle controls. No difference between individual treatment groups was present. For A and B, means are shown. ANOVA followed by Kruskal-Wallis analysis and a pairwise Wilcox test was used to analyze differences among groups. **p
Techniques Used: Concentration Assay, Staining, Infection
2) Product Images from "Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors"
Article Title: Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors
Figure Legend Snippet: In vitro antiviral effect of EIDD-1931, favipiravir, suramin and ribavirin in Vero cells. ( A ) Dose–response effect of EIDD-1931, favipiravir, suramin and ribavirin on MAYV-induced CPE (MOI 0.01), quantified in Vero cells by the MTS/PMS method. Data shown are mean values ± standard deviations (SD) from three independent experiments. ( B – E ) The effect of different concentrations of ( B ) EIDD-1931, ( C ) favipiravir, ( D ) suramin and ( E ) ribavirin on the release of MAYV particles by infected Vero cells (MOI 0.01). Both viral RNA (genome copies/mL; blue) and infectious progeny virus (TCID 50 /mL; orange) were quantified at 48 h pi by real-time qRT-PCR and end-point titrations, respectively. Data shown are mean values ± SD from three independent experiments. Significant differences from untreated virus control were analyzed by Kruskal–Wallis test (*, p
Techniques Used: In Vitro, Infection, Quantitative RT-PCR
Figure Legend Snippet: Mechanism of action of EIDD-1931, favipiravir and suramin against MAYV. Delay of treatment effect of favipiravir (blue), suramin (orange) and EIDD-1931 (green) on ( A ) intracellular RNA and ( B ) infectious virus titers, determined at 10 h pi, using qRT-PCR and end-point titrations, respectively. Vero cells were infected with MAYV TC625 (MOI 1) and compounds were added 2 h prior to infection (−2), at the time of infection (0) or 2, 4, 6, 8 h pi. Data shown are mean values ± SD from three (favipiravir and suramin) or four (EIDD-1931) experiments. Significant differences from untreated virus control were analyzed by Kruskal–Wallis test (*, p
Techniques Used: Quantitative RT-PCR, Infection